Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Adverse events: hair loss · SSNS in children
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects: leucopenia · SSNS in children
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Serious adverse events · non‐anaemic, iron‐deficient adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all infections · SSNS in children
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse event nausea and vomiting (0 to 24 hours) · SSNS in children
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
1 finding from 1 review
CNS adverse events · adults undergoing surgery
1 finding from 1 review
Maternal adverse events · pregnant women undergoing caesarean section
1 finding from 1 review
Adverse events · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Adverse events (e.g. the number of participants that died, or had arrhythmias, other heart rate disorders, or showed any signs of lidocaine toxicity) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events (e.g. the number of participants that died, or had arrhythmias, other heart rate disorders, or showed any signs of lidocaine toxicity) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · people with asthma
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
Withdrawals due to adverse events · IBD patients
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
1 finding from 1 review
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review